Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 11.2 mg (equivalent: tenofovir alafenamide, qty 10 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; iron oxide black - treatment of hiv-1 infection: descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy (see section 5.1 pharmacodynamic properties).,hiv-1 pre-exposure prophylaxis: descovy is indicated for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in at-risk adults and adolescents weighing at least 35 kg, excluding individuals at risk from receptive vaginal sex.

Australia - English - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - emtricitabine, quantity: 200 mg; tenofovir alafenamide fumarate, quantity: 28 mg (equivalent: tenofovir alafenamide, qty 25 mg) - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - treatment of hiv-1 infection: descovy is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and paediatric patients weighing at least 25kg. the patients must not have a history of treatment failure or known mutations associated with resistance to the individual components of descovy (see section 5.1 pharmacodynamic properties).,hiv-1 pre-exposure prophylaxis: descovy is indicated for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 in at-risk adults and adolescents weighing at least 35 kg, excluding individuals at risk from receptive vaginal sex.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - rilpivirine hydrochloride, quantity: 27.5 mg (equivalent: rilpivirine, qty 25 mg); dolutegravir, quantity: 50 mg - tablet, film coated - excipient ingredients: macrogol 3350; silicified microcrystalline cellulose; povidone; sodium starch glycollate type a; polyvinyl alcohol; microcrystalline cellulose; magnesium stearate; lactose monohydrate; iron oxide yellow; croscarmellose sodium; iron oxide red; mannitol; purified talc; titanium dioxide; sodium stearylfumarate; polysorbate 20 - juluca (dolutegravir/rilpivirine) is indicated for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adults who are virologically-suppressed (hiv-1 rna less than 50 copies per ml) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

four seasons agribusiness pty ltd - triclopyr present as the butoxyethyl ester; diethylene glycol monomethyl ether - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l; diethylene glycol monomethyl ether solvent other 226.0 g/l - herbicide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

upl australia pty ltd - triclopyr present as the butoxyethyl ester - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l - herbicide - commercial area - general | fallow crop land weed control | fenceline weed control | fire trail | firebreak weed control | fores - african boxthorn | angophora | australian or native blackthorn | banksia | bitter bark or quinine tree | black or brisbane black wattle | blackberry | brigalow | broadleaf hopbush | brooms | brown salwood or hickory wattle | budda or false sandalwood | camel or afghan melon | camphor laurel | camphor laurel - seedling | capeweed | castor oil bush | chilean cestrum | chinee apple | common prickly pear | dawson gum | english broom | english ivy | eucalyptus - see label for exceptions | eucalyptus - seedling up to 2 m tall | fennel | furze or gorse | green or early black wattle | groundsel bush | groundsel bush - seedling | horehound | lantana - lantana camara | narrow leaf hop bush | needlewood | olive - olea europaea | paddy melon | paperbark | prickly acacia | privet | rubber vine | saffron thistle | silver wattle | smooth tree or drooping prickly pear | st john's wort | sweet briar or wild rose | tiger pear | tree-of-heaven | turpentine bush | yellow wood | afghan melon | bitter melon | blackberry with st jo

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

halley international enterprise (australia) pty ltd - triclopyr present as the butoxyethyl ester - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l - herbicide - agricultural non-crop areas | commercial/industrial land | fallow land | fenceline weed control | fire trail | firebreak weed co - acacia genus | african boxthorn | angophora - regrowth | australian or native blackthorn | banksia - regrowth | bitter bark or quinine tree | blackberry | blackberry in assoc with other weed (see | brigalow | broadleaf hopbush | brooms | brown salwood or hickory wattle | budda or false sandalwood | camel or afghan melon | camphor laurel | capeweed | castor oil bush | chilean cestrum | chinee apple | common prickly pear | dawson gum | english broom | english ivy | eucalyptus | eucalyptus - see label for exceptions | eucalyptus - seedling and sucker | fennel | furze or gorse | green or early black wattle | groundsel bush | horehound | lantana - lantana camara | narrow leaf hop bush | needlewood | olive - olea europaea | paddy melon | paperbark | prickly acacia | privet | rubber vine | saffron thistle | silver wattle | smooth tree or drooping prickly pear | sweet briar or wild rose | tiger pear | tree-of-heaven | turpentine bush | yellow wood | afghan melon | bitter melon | black wattle | blackberry with dock |

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sinochem international australia pty. ltd. - triclopyr present as the butoxyethyl ester - emulsifiable concentrate - triclopyr present as the butoxyethyl ester pyridine-pyridinoxy active 600.0 g/l - herbicide - agricultural non-crop areas | commercial/industrial land | fallow crop land weed control | fenceline weed control | fire trail | - acacia genus | african boxthorn | angophora - regrowth | australian or native blackthorn | banksia - regrowth | bitter bark or quinine tree | black or brisbane black wattle | blackberry | blackberry in assoc with other weed (see | brigalow | broadleaf hopbush | brooms | brown salwood or hickory wattle | budda or false sandalwood | camel or afghan melon | camphor laurel | capeweed | castor oil bush | chilean cestrum | chinee apple | common prickly pear | dawson gum | english broom | english ivy | eucalyptus | eucalyptus - see label for exceptions | eucalyptus - seedling up to 2 m tall | fennel | furze or gorse | green or early black wattle | groundsel bush | horehound | lantana - lantana camara | narrow leaf hop bush | needlewood | olive - olea europaea | paddy melon | paperbark | prickly acacia | privet | rubber vine | saffron thistle | silver wattle | smooth tree or drooping prickly pear | sweet briar or wild rose | tiger pear | tree-of-heaven | turpentine bush | yellow wood | afghan melon | bitter melon | b

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

koppers performance chemicals australia pty ltd - copper (cu) present as copper naphthenate; liquid hydrocarbon - liquid - copper (cu) present as copper naphthenate mineral-copper active 20.0 g/l; liquid hydrocarbon solvent other 930.0 g/l - mixed function pesticide - hardwood timber | softwood timber - borer | fungal decay | decay fungi

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: potassium sorbate; castor oil; titanium dioxide; hypromellose phthalate; maltodextrin; carbomer 934; citric acid; silicon dioxide; xanthan gum; sucrose; povidone; flavour - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis. 6. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae; 7. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. klacid (clarithromycin) is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; 2. community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; 3. skin and skin structure infections (eg impetigo); 4. disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. 5. acute otitis media. note: 1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of klacid in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - darunavir, quantity: 800 mg; cobicistat, quantity: 150 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; crospovidone; silicon dioxide; magnesium stearate; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - prezcobix, a fixed dose combination of darunavir and cobicistat, is indicated in combination with other antiretroviral agents for the treatment of adult patients with human immunodeficiency virus- 1 (hiv-1) infection in:,- antiretroviral treatment-naive patients,- antiretroviral treatment-experienced patients with no darunavir resistance associated mutations and who have plasma hiv-1 rna <100,000 copies/ml,- antiretroviral treatment-experienced but hiv protease inhibitor-naive patients for whom hiv-1 genotype testing is unavailable (see section 4.2 dose and method of administration)